Intra-Cellular Therapies Inc. (ITCI) financial statements (2022 and earlier)

Company profile

Business Address 430 EAST 29TH STREET
NEW YORK, NY 10016
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4126010855464384475
Cash and cash equivalents926010855384947
Short-term investments320   427335428
Restricted cash and investments11     
Receivables2011   00
Inventory, net of allowances, customer advances and progress billings87     
Inventory87     
Prepaid expense   2   
Other undisclosed current assets25612123298548
Total current assets:467691230355469388483
Noncurrent Assets
Operating lease, right-of-use asset212418
Property, plant and equipment2221111
Other noncurrent assets0000000
Deferred tax assets, net11  
Other undisclosed noncurrent assets  0    
Total noncurrent assets:2326212211
TOTAL ASSETS:490717251357471389484
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities30202316853
Accounts payable96714642
Employee-related liabilities2115152211
Debt  3    
Other undisclosed current liabilities24161020653
Total current liabilities:5337363614116
Noncurrent Liabilities
Long-term debt and lease obligation192420    
Operating lease, liability192420
Liabilities, other than long-term debt   3332
Deferred revenue and credits332
Deferred rent credit   3
Other undisclosed noncurrent liabilities(19)(24)     
Total noncurrent liabilities:1924203332
Total liabilities:7260563917138
Stockholders' equity
Stockholders' equity attributable to parent418657195318454376476
Common stock0000000
Additional paid in capital1,6391,593905881862685670
Accumulated other comprehensive income (loss)(0)00(1)(1)(0)(1)
Accumulated deficit(1,221)(937)(710)(562)(407)(309)(193)
Total stockholders' equity:418657195318454376476
TOTAL LIABILITIES AND EQUITY:490717251357471389484

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues84230 000
Revenue, net000
Gross profit:84230 000
Operating expenses(369)(254)(154)(162)(103)(119)(106)
Operating loss:(286)(231)(154)(162)(103)(118)(106)
Nonoperating income
(Investment Income, Nonoperating)
2467431
Interest and debt expense     (0) 
Loss from continuing operations before income taxes:(284)(227)(148)(155)(99)(115)(105)
Income tax expense (benefit)(0)(0)(0)(0)1(1)(0)
Net loss available to common stockholders, diluted:(284)(227)(148)(155)(98)(116)(105)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(284)(227)(148)(155)(98)(116)(105)
Other comprehensive income (loss)(1)010(0)0(0)
Comprehensive loss, net of tax, attributable to parent:(285)(227)(147)(155)(98)(116)(105)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: